6 completed. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
Follow Uremia: new trials by email Literature Review of Uremia trials Research Report on Uremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) Spacing of Eculizumab infusions - Hemolytic-Uremic Syndrome, Atypical | Phase 3 | Completed | University Hospital, Tours | 40 | 2021-10-20 | 2025-03-25 |
| Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Ravulizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 34 | 2017-08-31 | 2024-03-15 |
| Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Ravulizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2017-01-11 | 2024-02-20 |
| Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Eculizumab, Placebo - Hemolytic Uremic Syndrome of Childhood | Phase 3 | Completed | University Hospital, Toulouse | 100 | 2015-06-01 | 2026-05-04 |
| Effects of Convective Therapies in Dialysis Patients online pre-dilution hemofiltration, online pre-dilution hemodiafiltration - Uremia | Phase 3 | Completed | A. Manzoni Hospital | 146 | 2003-11-01 | 2012-04-24 |
Atypical Hemolytic Uremic Syndrome (4) · Hemolytic-Uremic Syndrome (2) · Thrombotic Microangiopathies (2) · Kidney Diseases (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Anemia (5) · Anemia, Hemolytic (5) · Blood Platelet Disorders (5) · Cytopenia (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Kidney Diseases (5) · Thrombocytopenia (5) · Hemolytic-Uremic Syndrome (3)
ravulizumab (2) · Glucose (1) · Solutions (1) · eculizumab (1) · iptacopan (1)
Alexion Pharmaceuticals, Inc. (2) · A. Manzoni Hospital (1) · Novartis Pharmaceuticals (1) · University Hospital, Toulouse (1) · University Hospital, Tours (1)
France (3) · Italy (3) · South Korea (3) · United States (3) · Belgium (2) · Germany (2) · Japan (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · China (1)
Arnaud Garnier, MD (1) · Francesco Locatelli, Professor (1) · Karine Brochard (1)
PMID 33783815, PMID 20813866, PMID 24557989, PMID 32299680, PMID 33048203, PMID 33407224, PMID 33693990, PMID 33774745, PMID 34169200, PMID 34219224, PMID 35123930, PMID 36329366, PMID 37303085, PMID 39105067, PMID 39468592, PMID 40277027
2016 (2), 2014 (1)